Jason Daily, MD
Endocrinology, Diabetes & Metabolism · Fayetteville, ARNPI 1043290836
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 74.9% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2019 at $24,501 and has fallen 89.0% since, to $2,696 in 2025.
Across 544 payments — averaging $64.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$26K
- Medtronic$1K
- Novo Nordisk$860
- Lilly USA, LLC$796
- Sanofi-aventis U.S. LLC$741
- Insulet Corporation$706
- plus $5K from 39 others
What the payments were for
- Speaking & faculty fees$20,50058%
- Travel & lodging$2,9068%
- Food & beverage$11,56433%
- Education$1180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$19,486
- EVENITY$5,053
- iLet Bionic Pancreas$708
- MINIMED 780G$379
- DEXCOM G7 GSS (161)$250
- TZIELD$246
- Repatha$235
- TOUJEO$125
- Wegovy$121
- Omnipod$114
- TEPEZZA$113
How this compares
$35,088 in reported general payments places this provider in the 75th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
See all endocrinology, diabetes & metabolism providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 12 | $1,769,267 |
| OzempicSemaglutide | 756 | $868,435 |
| MounjaroTirzepatide | 344 | $402,028 |
| TrulicityDulaglutide | 288 | $365,573 |
| JardianceEmpagliflozin | 303 | $280,553 |
| Tresiba Flextouch U-200Insulin Degludec | 233 | $202,331 |
| Tresiba Flextouch U-100Insulin Degludec | 343 | $198,448 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 245 | $191,337 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 106 | $184,391 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 155 | $156,396 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 109 | $139,614 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 216 | $95,809 |
| Novolog FlexpenInsulin Aspart | 374 | $87,905 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 170 | $81,568 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 80 | $78,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq, Farxiga | $176 | $1,805,39952 claims |
| Novo NordiskOzempic, Fiasp, Novolog, Rybelsus, Xultophy 100-3.6 | $860 | $968,050911 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $796 | $790,236727 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $437 | $440,095435 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $741 | $22,14322 claims |
| AbbVieSynthroid | $238 | $15,464196 claims |
| MerckJanuvia | $40 | $11,36114 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $39 | $10,8111,362 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
Other endocrinology, diabetes & metabolism in Fayetteville
- Catherine KilpatrickFayetteville$690K
- Lauren HawkinsFayetteville$4K
- Richard GriffithsLittle Rock$925K
- Adam MaassSpringdale$502K
- James ThrasherLittle Rock$349K
- Kevin GanongJonesboro$131K
- Cory GambleFort Smith$112K
- Chitharanjan DuvoorJonesboro$76K
- Richard RappLittle Rock$47K
- Shunzhong BaoLittle Rock$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.